Clinical value and applicability of radiomics in differential diagnosis of dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Table 2 Clinical data and imaging characteristics of dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Variable	b value	OR value	95%CI	P value
Sex	-0.018	0.917	0.954-1.003	0.587
Age	0.008	1.008	0.977-1.041	0.601
TBIL	-0.002	0.998	0.992-1.000	1.351
ALT	1.358	3.889	0.629-24.049	0.144
AST	0.936	2.55	1.949-3.335	2.934
ALB	-0.671	0.511	0.108-2.413	0.397
AFP	1.076	2.933	1.225-7.021	0.016
PLT	0.388	1.474	0.423-5.142	0.542
HBV	-0.988	0.372	0.089-1.561	0.177
Cirrhosis	0.103	1.109	1.062-1.157	0.000
MTD	0.001	1.001	0.977-1.024	0.06
Margin	-0.988	0.372	0.089-1.561	0.177
Shape	0.996	2.707	0.830-8.828	2.707
Dense	-1.406	0.245	0.042-1.428	0.245
Cholangiectasis	0.985	2.678	0.997-7.191	0.051
Artery within tumor	1.421	4.137	0.924-18.503	0.064
Nonrim APHE	0.081	1.084	0.314-3.741	0.898
Nonperipheral washout	0.598	1.765	0.785-3.965	0.068
Halo sign	-0.172	0.73	0.39-1.49	0.267
Capsule	0.228	1.07	0.29-1.84	0.098
Cystoid variation and necrosis	0.073	1.076	0.238-4.864	0.924
Peritumoral enhancement	0.097	1.102	1.033-1.176	0.003

TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; AFP: Alpha-fetoprotein; PLT: Platelet; HBV: Hepatitis B virus; MTD: Maximum tumor diameter; APHE: Arterial phase hyperenhancement.